{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Elutia, Inc. Stock Plummets to New 52-Week Low of $1.03
Elutia, Inc., a microcap pharmaceutical company, has hit a new 52-week low, reflecting a significant decline in its stock price over the past year. With a market cap of around USD 80 million, the company faces financial challenges, including negative EBITDA and declining sales, indicating potential instability and weak growth prospects.
Elutia, Inc. Stock Plummets to New 52-Week Low of $1.06
Elutia, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low, reflecting a challenging year with a significant stock price decline. The company faces financial difficulties, including negative cash flow and declining sales, raising concerns about its long-term viability in the industry.
Is Elutia, Inc. technically bullish or bearish?
As of September 9, 2025, Elutia, Inc. is in a bearish trend, indicated by negative technical indicators and a year-to-date return of -71.12%, significantly underperforming the S&P 500's 12.22%.
Is Elutia, Inc. overvalued or undervalued?
Elutia, Inc. is considered overvalued and risky due to negative valuation ratios and a year-to-date return of -71.12%, significantly underperforming compared to the S&P 500's gain of 12.22%.
Elutia, Inc. Stock Plummets to New 52-Week Low of $1.08
Elutia, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, has hit a new 52-week low, reflecting a challenging year with a significant stock price decline. The company faces financial difficulties, including negative book value, declining net sales, and substantial operating losses, raising concerns about its long-term viability.
Elutia, Inc. Stock Plummets to New 52-Week Low of $1.13
Elutia, Inc., a microcap pharmaceutical company, has reached a new 52-week low, reflecting a challenging year with a significant stock price decline. The company operates at a loss, has a negative book value, and faces difficulties with declining net sales and poor financial metrics, including negative operating cash flow.
Elutia, Inc. Stock Plummets to New 52-Week Low of $1.17
Elutia, Inc., a microcap pharmaceutical company, has reached a new 52-week low, reflecting a challenging year with a significant stock price decline. The company faces financial difficulties, including negative operating cash flow and declining net sales, indicating struggles with long-term growth and market position.
Is Elutia, Inc. overvalued or undervalued?
Elutia, Inc. is currently considered undervalued and classified as "risky" due to negative financial ratios, including a P/E of -2.5964, and has significantly underperformed the S&P 500 with a year-to-date return of -53.48%.
Is Elutia, Inc. technically bullish or bearish?
As of April 1, 2025, Elutia, Inc. is in a bearish trend, supported by strong bearish signals from the MACD, moving averages, and Bollinger Bands, despite a bullish weekly RSI.
Who are in the management team of Elutia, Inc.?
As of March 2022, the management team of Elutia, Inc. includes Mr. Kevin Rakin as Chairman of the Board and Mr. Ron Lloyd as President, CEO, and Director.
What does Elutia, Inc. do?
Elutia, Inc. is a regenerative medicine company focused on developing products for surgical patients, particularly those with implantable medical devices. As of March 2025, it reported net sales of $6 million and a net loss of $4 million, with a market cap of $72.77 million.
How big is Elutia, Inc.?
As of Jun 18, Elutia, Inc. has a market capitalization of 72.77 million and reported net sales of 23.71 million with a net profit of -40.28 million over the latest four quarters. As of Dec 24, shareholder's funds were -46.26 million and total assets were 36.13 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
